CA2573456A1 - Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers - Google Patents

Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers Download PDF

Info

Publication number
CA2573456A1
CA2573456A1 CA002573456A CA2573456A CA2573456A1 CA 2573456 A1 CA2573456 A1 CA 2573456A1 CA 002573456 A CA002573456 A CA 002573456A CA 2573456 A CA2573456 A CA 2573456A CA 2573456 A1 CA2573456 A1 CA 2573456A1
Authority
CA
Canada
Prior art keywords
liver
use according
ddc
liver disease
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002573456A
Other languages
English (en)
French (fr)
Inventor
Eleonore Froehlich
Ivica Kvietikova
Kurt Zatloukal
Gottfried Schatz
Helmut Denk
Cornelia Stumptner
Charles Buck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ORIDIS BIOMED FORSCHUNGS- und ENTWICKLUNGS GmbH
Original Assignee
Eleonore Froehlich
Ivica Kvietikova
Kurt Zatloukal
Gottfried Schatz
Helmut Denk
Cornelia Stumptner
Charles Buck
Oridis Biomed Forschungs- Und Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eleonore Froehlich, Ivica Kvietikova, Kurt Zatloukal, Gottfried Schatz, Helmut Denk, Cornelia Stumptner, Charles Buck, Oridis Biomed Forschungs- Und Entwicklungs Gmbh filed Critical Eleonore Froehlich
Publication of CA2573456A1 publication Critical patent/CA2573456A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA002573456A 2004-07-13 2005-07-12 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers Abandoned CA2573456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103318 2004-07-13
EP04103318.4 2004-07-13
PCT/EP2005/053338 WO2006005759A2 (en) 2004-07-13 2005-07-12 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers

Publications (1)

Publication Number Publication Date
CA2573456A1 true CA2573456A1 (en) 2006-01-19

Family

ID=34929318

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002573456A Abandoned CA2573456A1 (en) 2004-07-13 2005-07-12 Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers

Country Status (11)

Country Link
US (1) US20070225255A1 (ja)
EP (1) EP1765413A2 (ja)
JP (1) JP2008506667A (ja)
CN (1) CN1997403A (ja)
AU (1) AU2005261654A1 (ja)
CA (1) CA2573456A1 (ja)
IL (1) IL179738A0 (ja)
RU (1) RU2007105138A (ja)
SG (1) SG156613A1 (ja)
WO (1) WO2006005759A2 (ja)
ZA (1) ZA200609635B (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01881B (me) 2004-01-22 2014-12-20 Univ Miami Topijske formulacije koenzima q10 i postupci upotrebe
US20080032940A1 (en) * 2006-08-07 2008-02-07 Balaraman Kalyanaraman Methods for reducing anthracycline-induced toxicity
EP2095713A1 (en) 2006-10-20 2009-09-02 Limited Liability Company "Mitotechnology" Composition for regenerating and stimulating growth of plants and for adapting plants to different stress factors
EA200900582A1 (ru) 2006-10-20 2009-08-28 Общество С Ограниченной Ответственностью "Митотехнология" Фармацевтические композиции для профилактики и лечения глазных патологий
WO2008094062A1 (fr) 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques servant à la prévention et au traitement de maladies oncologiques
WO2008094061A1 (fr) 2007-01-29 2008-08-07 Limited Liability Company 'mitotechnology' Compositions pharmaceutiques et cosmétiques servant à accélérer le processus de cicatrisation de plaies et autres lésions superficielles
EA201000142A1 (ru) 2007-04-11 2010-04-30 Общество С Ограниченной Ответственностью "Митотехнология" Композиция, замедляющая старение и увеличивающая продолжительность жизни организма, и ее применение
US8518915B2 (en) 2007-06-29 2013-08-27 Mitotech Sa Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases
WO2009033130A1 (en) * 2007-09-07 2009-03-12 Gencia Corporation Mitochondrial compositions and uses thereof
US8388936B2 (en) * 2008-02-22 2013-03-05 Mcw Research Foundation, Inc. In vivo mitochondrial labeling using positively-charged nitroxide enhanced and gadolinium chelate enhanced magnetic resonance imaging
US8388931B2 (en) * 2008-02-29 2013-03-05 Marcos Lopez 99m Tc-labeled triphenylphosphonium derivative contrasting agents and molecular probes for early detection and imaging of breast tumors
KR20100136997A (ko) 2008-04-11 2010-12-29 싸이토테크 랩스, 엘엘씨 암세포에서 아폽토시스를 유도하는 방법 및 용도
WO2010056145A1 (ru) 2008-11-12 2010-05-20 Общество С Ограниченной Ответственностью "Митотехнология" Способ умеренного повышения протонной проводимости биологических мембран при помощи митохондриально- адресованных делокализованных катионов
SG175251A1 (en) * 2009-04-17 2011-11-28 Colby Pharmaceutical Company Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
CA2761717A1 (en) 2009-05-11 2010-11-18 Berg Biosystems, Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
ES2527791T3 (es) 2009-06-10 2015-01-29 Mitotech Sa Composición farmacéutica para su uso en oftalmología médica y veterinaria
AU2009355359B2 (en) 2009-11-13 2016-11-10 Mitotech S.A. Pharmaceutical substances on the basis of mitochondrially addressed antioxidants
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
JP6448366B2 (ja) 2011-06-03 2019-01-09 ミトテック ソシエテ アノニム ミトコンドリアを標的とする抗酸化剤の経口製剤ならびにそれらの調製および使用
WO2013043580A2 (en) * 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
MX2015014097A (es) 2013-04-08 2016-06-07 Berg Llc Tratamiento de cancer empleando terapias combinadas de coenzima q10.
PL2989110T3 (pl) * 2013-04-24 2019-03-29 Smart Brain s.r.o. Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
KR101773404B1 (ko) 2015-08-25 2017-08-31 (주) 씨유스킨 자외선에 의한 피부 손상의 예방 또는 개선을 위한 화장료 조성물
CN107510848A (zh) * 2016-06-15 2017-12-26 常州莱道斯生物医药科技有限公司 线粒体靶向制剂MitoPBN在防治糖尿病中的应用
CN108201543A (zh) * 2016-12-19 2018-06-26 北京福纳康生物技术有限公司 水溶性富勒烯结构在制备治疗脂肪肝的药物中的应用
CN115381804A (zh) * 2022-08-10 2022-11-25 华南师大(清远)科技创新研究院有限公司 癸基泛醌在制备治疗肝纤维化药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722361D0 (en) * 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
CA2354743A1 (en) * 2001-08-07 2003-02-07 University Of Otago Mitochondrially targeted antioxidants
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
BRPI0413742B8 (pt) * 2003-08-22 2021-05-25 Antipodean Pharmaceuticals Inc composto antioxidante quimicamente estável, composição farmacêutica, método de redução do estresse oxidativo em uma célula in vitro e métodos de preparo e de síntese do referido composto antioxidante

Also Published As

Publication number Publication date
IL179738A0 (en) 2007-05-15
JP2008506667A (ja) 2008-03-06
ZA200609635B (en) 2008-08-27
WO2006005759A2 (en) 2006-01-19
US20070225255A1 (en) 2007-09-27
WO2006005759A3 (en) 2006-05-11
CN1997403A (zh) 2007-07-11
EP1765413A2 (en) 2007-03-28
AU2005261654A1 (en) 2006-01-19
RU2007105138A (ru) 2008-08-20
SG156613A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
CA2573456A1 (en) Mitochondrially targeted antioxidants in the treatment of liver diseases and epithelial cancers
Wu et al. Cannabidiol induced apoptosis in human monocytes through mitochondrial permeability transition pore-mediated ROS production
Fetoni et al. In vivo protective effect of ferulic acid against noise-induced hearing loss in the guinea-pig
Sergent et al. Role for membrane fluidity in ethanol-induced oxidative stress of primary rat hepatocytes
Persson et al. Prevention of oxidant-induced cell death by lysosomotropic iron chelators
Raghunandhakumar et al. Thymoquinone inhibits cell proliferation through regulation of G1/S phase cell cycle transition in N-nitrosodiethylamine-induced experimental rat hepatocellular carcinoma
Yuan et al. Novel di-2-pyridyl–derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment
Sims et al. Ringer’s ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats
Dumont et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: measurement with recombinant human annexin-V in a mouse model
Macias et al. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock
Shteinfer‐Kuzmine et al. Selective induction of cancer cell death by VDAC 1‐based peptides and their potential use in cancer therapy
Cheshchevik et al. Rat liver mitochondrial damage under acute or chronic carbon tetrachloride-induced intoxication: protection by melatonin and cranberry flavonoids
Solazzo et al. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines
Steenkamp et al. The effect of Senecio latifolius a plant used as a South African traditional medicine, on a human hepatoma cell line
Abd-Elbaset et al. Thymoquinone mitigate ischemia-reperfusion-induced liver injury in rats: a pivotal role of nitric oxide signaling pathway
Babu et al. Antioxidant potential of CORM-A1 and resveratrol during TNF-α/cycloheximide-induced oxidative stress and apoptosis in murine intestinal epithelial MODE-K cells
Terada et al. 5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo
Bavisotto et al. The dissociation of the Hsp60/pro-Caspase-3 complex by bis (pyridyl) oxadiazole copper complex (CubipyOXA) leads to cell death in NCI-H292 cancer cells
Duvigneau et al. Reperfusion does not induce oxidative stress but sustained endoplasmic reticulum stress in livers of rats subjected to traumatic-hemorrhagic shock
Xu et al. Curcumin protects rat heart mitochondria against anoxia–reoxygenation induced oxidative injury
Cheng et al. Ebselen protects rat hearts against myocardial ischemia‑reperfusion injury
WO2020257224A1 (en) Biothiol-activatable probe and method of use
Taguchi et al. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal
Ommati et al. Silymarin mitigates bile duct obstruction-induced cholemic nephropathy
Potje et al. Mechanisms underlying the hypotensive and vasodilator effects of Ru (terpy)(bdq) NO] 3+, a nitric oxide donor, differ between normotensive and spontaneously hypertensive rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued